Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (148)	6/18/1997 10:00:00 AM
From: Dr. John M. de Castro	of 1494

This article is much more important than it appears on the surface. Thanks for posting it Miljenko! As you have pointed out, NTII's memantine patents do not include treatment for ischemic brain damage. However, the patent does include treatment for patients with homcysteineuria. This article clearly indicates that elevated homocysteine levels are present in large numbers of stroke patients and is even a risk factor for stroke. I've been assured by a very knowledgeble source that NTII's memantine patent covers stroke associated with elevated homocysteine levels. Since, this includes most stroke patients, NTII effectively has rights to treat this ischemic disorder with memantine. Memantine has wide applicability for neuroprotection and the NTII patent rights cover all of these indications except ischemia. This new link with homocysteineuria, however, changes that, and means that the patent rights even extend to ischemia. Hence, it is a potential direct competitor of CNSI's Cerestat. IMO memantine has the greater potential to have the proper combination of safety and efficacy. The article also suggests that memantine could be used by patients at risk for stroke as a prophylatic. Since it can be take orally and has minimal side effects, it is possible that patients with elevated homocysteine levels at risk for stroke, may be prescribed memantine to prevent the occurrence of a stroke. This opens up an immense and chronic, rather than acute, market for memantine. Not too shabby for a company with a Market Cap of $16MM ! John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next